Best Practices for Technology Transfer - Clear documentation and open communication are essential for effective technology transfer. - BioPharm International

ADVERTISEMENT

Best Practices for Technology Transfer
Clear documentation and open communication are essential for effective technology transfer.


BioPharm International
Volume 24, Issue 6, pp. 50-54, 57

METHODOLOGY


Figure 1: Schematic workflow diagram of an effective technology transfer practice. (ALL FIGURES COURTESY OF THE AUTHORS)
Figure 1 demonstrates an example of effective technology transfer practice used when a fully developed production process is transferred from a sending company to a receiving company for GMP manufacturing of a biopharmaceutical product. The technology transfer activities often start with the transfer of documents from the technology sending site to the receiving site. The technology transfer document package and technical communications between both sites should provide sufficient process understanding at the receiving site. With understanding of the process and the product requirement, the GMP manufacturing process can be designed on paper.

If GMP manufacturing is attempted at this stage based on the design on paper, the chance of success would be slim. Confirming technical feasibility and performance of the designed GMP-scale process by a small-scale prototype process would minimize the risk at lower cost. Therefore, a small-scale prototype process is designed and executed by directly scaling-down the designed GMP process. The designed GMP process may undergo redesign or changes based on any technical unsuitability experienced during the execution of small-scale runs and after evaluating the performance of small-scale prototype process runs.

Not all parameters and conditions applicable in a large-scale process can be mimicked exactly in a small-scale prototype run. Therefore, a full GMP scale process run, often called an engineering or technical run, using the GMP batch production protocols and equipment prior to the actual GMP runs, justifies the success of the GMP batch at first attempt. The product produced from such a successful engineering run can also be used for preclinical studies, a stability study, or assay qualification or validation. The design of the GMP process may again undergo redesign or changes based on the technical feasibility and performance of the engineering run.

THE DOCUMENT PACKAGE

Transferring documents containing the process description is usually the first activity to take place during a technology transfer program after the business agreement is signed. A typical technology transfer package includes the following documents:

  • Process description: It is the responsibility of the sending site to provide a detailed description of the final process they would like to transfer. The process description should contain all process parameters and conditions, and be as detailed as possible. Some important parameters that a process description must contain can be found in the next section of this article.
  • Production protocols: Prior to, or at the early stage of technology transfer, the developed final process is run a few times at the site where it was developed. The availability of production protocols should provide the details of how each process step was originally performed, which are typically not covered in a process description document.
  • Process development report: The process development site must document why certain decisions were taken and why certain parameters or conditions were selected while others are not during process development. Availability of this document to the technology receiving site allows understanding of critical process parameters and enables decisions about how to execute each process step with acceptable margin of all parameters and conditions.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here